Please assess the completion status of the following clinical trial:

Trial Title: Nasal Tramazoline and Dexamethazone in Obstructive Sleep Apnea (OSA) Patients Tramazoline and

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. OSA patients (AHI \> 10 events/h), and~2. normal nasal resistance measured in seated and supine position with active anterior and posterior rhinomanometry (\< 3.0 cmH20•L-1•s).~Exclusion Criteria:~1. recent surgery involving the upper airways,~2. central apnoeas more than three per hour or five percent of total apnoeas,~3. total sleep time during polysomnographies less than three hours,~4. current treatment with nasal decongestants and topical steroids, and~5. upper or lower respiratory tract disease, including a history of nasal allergy, and~6. smoking.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- nasal spray with tramazoline and dexamethazone (Type: ACTIVE_COMPARATOR): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).